Jiangshang Huang

Immune checkpoint inhibitors (ICIs), such as anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and anti-programmed cell death protein 1 (PD-1), have revolutionized cancer treatment and survival. However, ICIs can lead to immune-related adverse events, notably colitis…